Sugi Predict

Sugi Predict / Compounds / SCHEMBL23270010

SCHEMBL23270010

SCHEMBL23270010

CC(C)(C)OC(=O)N1CCN(CC2CCN(Cc3ccccc3)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 4/20 0.53
▸ THRB P10828 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ CHRM4 P08173 4/20 0.53
▸ ACHE P22303 3/20 0.50
▸ BCHE P06276 2/20 0.50
▸ GPR119 Q8TDV5 2/20 0.50
▸ STS P08842 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20274773 0.96 TP53 (0.50) TP53THRBMAPTKDM4EPKM
SCHEMBL14497204 0.93 KDM4E (0.51) TP53THRBMAPTKDM4EPKM
SCHEMBL641206 0.90 KDM4E (0.52) TP53THRBMAPTKDM4EPKM
SCHEMBL642365 0.90 KDM4E (0.52) TP53THRBMAPTKDM4EPKM
SCHEMBL641207 0.90 KDM4E (0.52) TP53THRBMAPTKDM4EPKM
SCHEMBL2862442 0.89 ALDH1A1 (0.60) TP53THRBMAPTKDM4ECHRM4
SCHEMBL30816870 0.88 CYP2D6 (0.55) TP53THRBMAPTKDM4EPKM
SCHEMBL18921646 0.86 SMN1; SMN2 (0.56) KDM4EPKMGPR119STS
SCHEMBL2386800 0.86 SMN1; SMN2 (0.56) KDM4EPKMGPR119STS
SCHEMBL31138169 0.86 TP53 (0.47) TP53THRBMAPTKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041429-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF UBIX THERAPEUTICS, INC. (KR) 2025-02-06 — — US disclosed
EP-4428130-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF Ubix Therapeutics, Inc. (KR) 2024-09-11 — — EP disclosed
CN-118159532-A Compound with BTK protein degradation activity and medical application thereof 尤比克斯治疗公司 2024-06-07 — — CN disclosed
WO-2023080732-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF 주식회사 유빅스테라퓨틱스 2023-05-11 — — WO disclosed
WO-2023080732-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF 주식회사 유빅스테라퓨틱스 2023-05-11 — — WO disclosed
US-20210147385-A1 COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-05-20 — — US disclosed
WO-2021076886-A1 3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041429-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF BTK, LYN, SYK TP53 287/4885THRB 2419/4885MAPT 3790/4885
US-20210147385-A1 COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS TEK, KDR, LIPG TP53 1187/4885THRB 4268/4885MAPT 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.